1Appelbaum PC, Gillespie SH, Burley CJ, et al. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st Century: a review of gemifloxaein[J]. Int J Antimierob Agents,2004,23(6) :533-546.
2Grossman RF,Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting[J]. Am J Med,2005,118(7A) : 29S-38S.
3Lionel A, Mandell, Richard G,et al. Infectious Disease Society of Amercian/Amereian Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults[s]. Clin Infect Dis, 2007,44 : S27-S72.
6Gotfried MH. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999- 2000 respiratory surveillance program[J]. Am J Med,2001,111(9A) :25S-29S; discussion 36S-38S.
7Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxaein and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia[J]. Clin Ther, 2002,24 (8): 1292-1308.
8File TM Jr,Milkovich G,Tennenberg AM,et al. Clinical implications of 750 rag, 5-day levofloxacin for the treatment of community-acquired pneumonia[J]. Curr Med Res Opin, 2004,20(9) : 1473-1481.
9Dunbar LM,Khashab MM,Kahn JB,et al. Efficacy of 750 mg, 5 day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens[J]. Curr Med Res Opin,2004,20 (4) :555-563.
10Lode H,File TM ]r,Mandell L,et at. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a maerolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multieenter study of clinical efficacy and tolerability[J]. Clin Ther, 2002,24(11) : 1915-1936.
4Allen A,Bygate E,Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers[J].Antimicrob Agents Chemother,2001,45(2):540-545.
5Gee T,Andrews JM,Ashby JP,et al.Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose[J].J Antimicrob Chemother,2001,47(4):431-434.
6Allen Avousden M,Lewis A.Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers[J].Chemotherapy Basel,1999,45(6):496-503.
7File TM,Schlemmer JB.Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia:a randomized,double-blind comparison with trovafloxacin[J].J Antimicro Chemother,2001,48(1):67-74.
8File T,Schlemmer B,Garau J.Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis[J].J Chemother,2000,12(4):314-325.
9Lode H,File TM Jr,Mandell L,et al.185 Gemifloxacin Study Group.Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia:a randomized,open-label,multicenter study of clinical efficacy and tolerability[J].Clin Ther,2002,24(11):1915-1936.
10Tanaka M, Otsuki M, Une T, et al. In - vitro and in - vivo activity of DR - 3355, an optically active isomer of ofloxacin [ J ]. J Antimicrob Chemother, 1990 ;26: 659 - 666.
